# Insider Monkey

Type: Company

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/insider-monkey
Canonical HTML page: https://getbiobrief.com/entity/insider-monkey

## Recent coverage (1 stories)

### CyPath Lung: 92% Sensitivity, 99% NPV Drive bioAffinity's Surveillance Pivot
2026-09-05 14:59:18 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

bioAffinity is leveraging strong clinical data from CyPath Lung, including 92% sensitivity and 99% negative predictive value, to move into post-treatment surveillance. The expansion could broaden the diagnostic's target population beyond initial pulmonary nodule assessment.
Full story: https://getbiobrief.com/story/cypath-lung-sensitivity-npv-surveillance-bio

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.